A rapid and effective antidote for anticoagulant bleeds

August 30, 2016

This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2016. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.

Rome, Italy - 30 August, 2016: A specially designed antidote to reverse acute, potentially life-threatening anticoagulant-related bleeding worked quickly, and was well-tolerated according to interim results of the ongoing ANNEXA-4 study.

Andexanet alfa reduced anticoagulant activity by roughly 90% within half an hour among patients with acute major bleeding while receiving a factor Xa (fXa) inhibitor, resulting in "excellent or good" homeostatis at 12 hours in most subjects, reported lead investigator Stuart J. Connolly, MD, from McMaster University, in Hamilton Ontario, Canada.

The ANdexanet Alfa, a Novel Antidote to the Anticoagulation Effects of FXA Inhibitors (ANNEXA-4) study was presented at ESC Congress 2016, with simultaneous publication in The New England Journal of Medicine.

"Andexanet is the first specific agent designed for reversal of factor X inhibitors. Although it has been shown to reduce anti-fXa activity in volunteers, until now we did not have experience in acutely bleeding patients. In these patients andexanet reduced the anticoagulant effect of the factor Xa inhibitors and was associated with effective haemostasis in most patients," according to Dr. Mark Crowther, ANNEXA-4 co-principal investigator, also from McMaster University.

The interim results include 67 patients, mean age 77 years, who required urgent reversal of acute major bleeding within 18 hours of receiving either a direct (apixaban, rivaroxaban, edoxaban) or indirect (enoxaparin) fXa inhibitor.

The primary site of bleeding was gastrointestinal 49% of patients, and intracranial in 42%.

For ethical reasons, the study was not randomised, and all patients received andexanet - first in an immediate bolus over 15-30 minutes, followed by a 2 hour infusion. Dosing was based on which fXa inhibitor they had been exposed to, and when.

Patients were assessed at baseline, end-of-bolus, and end of the 2-hour infusion, as well as at 4, 8, and 12 hours, and 3 and 30 days post-infusion.

Among 47 patients included in the efficacy assessment, there was an 89% decrease in anti-fXa activity from baseline to end-of-bolus for those exposed to rivaroxaban (n=26), and a corresponding 93% reduction for those exposed to apixaban (n=20).

At 12 hours, clinical hemostatic efficacy was rated as "good to excellent" in 79% of patients.

Thrombotic events occurred in 18% of subjects during 30 day follow up. "This rate of events is not unexpected considering the thrombotic potential of the patients and the fact that in most of them anticoagulation was discontinued at the time of bleeding and not restarted," said Dr. Connolly.

"This preliminary report of the ongoing ANNEXA-4 study shows us that andexanet rapidly reverses anti-factor Xa activity in acutely bleeding patients and this is associated with excellent or good hemostasis in most."
Notes to editors

Sources of funding: The study was funded by Portola Pharmaceuticals.

Disclosures: Both Dr. Connolly and Dr. Crowther have received research support and fees for consulting and lecturing from Portola Pharmaceutical Co.

ESC Press Office

For background information, please contact the ESC Press Office at media@escardio.org.

For press enquiries, please contact, the Media & Press Coordinator, Jacques Olivier Costa: +393427028575

For independent comment on site, please contact the ESC Spokesperson coordinator, Celine Colas: +393402405148

To access all the scientific resources from the sessions during the congress, visit ESC Congress 365.

About the European Society of Cardiology

The European Society of Cardiology brings together health care professionals from more than 120 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

About ESC Congress 2016

ESC Congress is the world's largest gathering of cardiovascular professionals contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2016 takes place 27 to 31 August at the Fiera di Roma in Rome, Italy. The scientific programme is here. More information is available from the ESC Press Office at press@escardio.org

European Society of Cardiology

Related Bleeding Articles from Brightsurf:

Blood-thinner with no bleeding side-effects is here
In a study led by EPFL, scientists have developed a synthetic blood-thinner that, unlike all others, doesn't cause bleeding side-effects.

Rate over time of stroke caused by brain bleeding
This observational study looked at the rate and risk factors of stroke caused by bleeding within the brain (intracerebral hemorrhage) between 1948 and 2016 among 10,000 participants in the Framingham Heart Study.

Soil in wounds can help stem deadly bleeding
New UBC research shows for the first time that soil silicates--the most abundant material on the Earth's crust--play a key role in blood clotting.

Is headache from anesthesia after childbirth associated with risk of bleeding around brain?
This study examined whether postpartum women with headache from anesthesia after neuraxial anesthesia (such as epidural) during childbirth had increased risk of being diagnosed with bleeding around the brain (intracranial subdural hematoma).

Should patients continue blood thinners after experiencing gastrointestinal bleeding?
Anticoagulants and antiplatelet drugs, which are blood thinners such as warfarin and aspirin, are commonly taken to reduce the risk of potentially fatal blood clots, but they carry an increased risk of gastrointestinal bleeding.

Pharmacists in the ER speed delivery of coagulation drug to bleeding patients
A first-of-its-kind study has found that when a pharmacist is present in the emergency room, patients on blood thinners who experience life-threatening bleeding receive a live-saving coagulation drug much more quickly.

Internal bleeding after heart attack may trigger suspicion of cancer
Bleeding during the first six months after discharge from hospital for a heart attack is linked with a subsequent cancer diagnosis, according to research presented today at ESC Congress 2019 together with the World Congress of Cardiology.

One in five haematological cancer patients suffer blood clots or bleeding
In the years following haematological cancer, one in five survivors suffer a blood clot or bleeding which requires hospital treatment.

Reversal agent decreases life-threatening bleeding
The blood thinner reversal agent - andexanet alfa -was effective at stopping acute major bleeding in patients taking factor Xa inhibitor blood thinners.

Draining blood from bleeding stroke may prevent death
A minimally invasive surgery combining the use of a clot-busting drug and a catheter to drain blood from the brain of hemorrhagic stroke patients reduced swelling and improved patients' prognoses, according to preliminary research.

Read More: Bleeding News and Bleeding Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.